

Pompe disease and its differential diagnosis

Ichizo Nishino, MD, PhD

Department of Neuromuscular Research National Institute of Neuroscience National Center of Neurology and Psychiatry (NCNP)

nishino@ncnp.go.jp

MAT-HK-2300786-1.0-10/2023

Hong Kong October 14, 2023

Disclosures

- Honoraria
 - Japan Blood Products Organization
 - Sanofi
 - Medical & Biological Laboratories
- SAB /RAB /Consultant
 - Nobel Pharma
 - UCB Biopharma SRL
 - Sarepta Therapeutics
 - Astellas Pharma
 - Horizon Therapeutics
 - Argenx

Disclaimers

- These presentation materials have been prepared for medical and scientific information sharing/ exchange purposes and not intended to encourage the use of any product mentioned therein in any manner inconsistent with the label approved by local regulatory authority.
- Sanofi does not recommend nor encourage the use of any product in any manner inconsistent with the locally approved label.
- These presentation materials may include information about an investigational product still under clinical study or uses of a product that are outside the product's approved label in your country and may include information about preclinical studies or clinical studies that are still ongoing and maybe outside a product's approved label.

- Grants
 - Sanofi
 - CYTOO
 - Japan Agency for Medical Research and Development (AMED)
 - Ministry of Health, Labor and Welfare
 - Intramural (NCNP)

Pompe disease (GSD II)

- Acid α-glucosidase (acid maltase) deficiency
- **GAA** gene mutations
 - Autosomal recessive
 - 17q25.3
 - 754 disease-causing mutations (HGMD 2023.3)
- Enzyme replacement therapy
 - Alglucosidase alfa recombinant human GAA
 - Avalglucosidase alfa
 M6P-conjugated rhGAA
 - Cipaglucosidase alfa + miglustat
 M6P-conjugated rhGAA + chaperone



Joannes C. Pompe 1901-1945

Clinical features of Pompe disease

	Onset	Symptoms	Major cause of death
Infantile-onset (IOPD)	- 6m	Hypertrophic CM Hypotonia	Cardiac failure Respiratory failure
Late-onset	6m - Childhood	Proximal m. weakness	Respiratory failure
(LOPD)	Adulthood	Proximal m. weakness	Respiratory failure

Infantile-onset Pompe disease



Infantile-onset Pompe disease

Clinical features of Pompe disease

	Onset	Symptoms	Major cause of death
Infantile-onset (IOPD)	- 6m	Hypertrophic CM Hypotonia	Cardiac failure Respiratory failure
Late-onset	6m - Childhood	Proximal m. weakness	Respiratory failure
(LOPD)	Adulthood	Proximal m. weakness	Respiratory failure

Progressive proximal muscle loss in LOPD









CT





















Courtesy Dr. Madoka Mori, NCNP Hospital Muscle pathology

Infantile-onset



Infantile-onset

Acid phosphatase

Childhood-onset



Childhood-onset



Adult-onset





Enzyme replacement therapy

Early diagnosis!

Screening for Pompe disease

- Proximal weakness
- High CK
- Nonspecific MBx

Dried blood spot test



Clinicopathological findings of LOPD

Truly nonspecific?

Proximal weakness

Which muscle is most severely affected?

Consent given for video presentation **2y4m M, DMD**

Muscles used for standing up



Gowers sign in early DMD

= Difficulty extending hip joint



Consent given for video presentation **2y4m M, DMD**

a la segue

7y M DMD

Gluteus maximus

Quadriceps femoris









DMD



T1WI

Courtesy of Dr. Akihiko Ishiyama, NCNP Hospital

Imaging data



Motor function

LGMD2A/R1

Which is weaker?

hip extension or knee extension



Consent given for video presentation

12y M













Straub V, et al. Neuromuscul Disord. 2012

LOPD

Which is weaker?

hip extension or knee extension



Courtesy Dr. Madoka Mori, NCNP Hospital

LOPD



T1WI

Modified from Muscle Nerve. 2020 Nov 6. doi: 10.1002/mus.27099

Weak gluteus medius results in waddling gait



Hamdy, R., Saran, N. (eds) Pediatric Pelvic and Proximal Femoral Osteotomies. Springer, Cham. doi.org/10.1007/978-3-319-78033-7_1

LOPD 10y M



Courtesy of Dr. Keiko Ishigaki Tokyo Women's Medical University

遅発性ポンペ病(LOPD)は

1000

and K

0000

and to Access

10.11 E.100

CONTRACTOR OF

-

6

-

-

3

States and States

12

Trendelenburg gait in LOPD



Scapular winging in LOPD



LOPD

Atrophy in all periscapular muscles especially, subscapularis



Able to walk without assistance and not requiring ventilatory support



Able to walk without assistance and requiring ventilatory support



Unable to walk or only 10 meters or less if assisted and requiring ventilatory support

Neuromuscul Disord. 2011 Nov;21(11):791-9



FSHD1

CT



Courtesy of Dr. Takashi Kurashige NHO Kure Medical Center and Chugoku Cancer Center

Diagnostic finding of FSHD on MRI

Trapezius involvement Bil. Subscapularis sparing

MRI from 295 patients

- 187 FSHD
- 108 non-FSHD

Diagnostic accuracy 0.89 Sensitivity 0.90 Specificity 0.88

Respiratory failure

Marked diaphragm involvement in Pompe disease

43y F, autopsy



Respiratory failure before loss of ambulation in half of LOPD patients

Patient No.	1	2	3	4	5
Sex	Μ	Μ	F	F	F
Age at inclusion	66	55	44	38	32
Age at onset	35	35	20	8	7
Genotype	c.1585-1586TC>GT (p.S529V) homo	c.546G>T (p.T182T) homo	c.307T>C (p.C103R)/ c.546G>A (p.T182T)	NT	c.546G>T (p.T182T)/ c.1798C>T (p.R600C)
Observation period (week)	78	104	104	104	104
Symptom at onset	weakness of lower extremities	weakness of lower extremities	weakness of lower extremities	weakness of neck	weakness of lower extremities
Ventilator since (age)	58	49	36	32	21
Duration of ventilator use (year)	8	7	8	6	11
Ventilator use (hours /day)	24	10 (at night)	24	22	10 (at night)
Tracheotomy (age)	Ν	48	36	Ν	N
Wheelchair since (age)	51	48	36	36	29
Enzyme activity					
(M): muscle (nmols 4 MU/mg/30 min)					
(normal: 7.3±2.2)	0.6 (M)	0.3 (M)	0.94 (M)	0.46 (F)	0 (M)
(F): fibroblast (mmol/pg protein)					
(normal:161±32.4)					
Complications	diabetes mellitus	atrial fibrillation	interstitial pneumonia pneumothorax	Pneumothorax, subcutaneous/mediastinal emphysema	_
Muscle pathology	PAS-positive	Vacuoles stained with acid	Vacuoles stained with acid	Vacuoles stained with acid	Vacuoles stained with acid
	vacuoles	phosphatase	phosphatase	phosphatase	phosphatase

Furusawa et al. J Inherit Metab Dis 2012

Muscle disease with early respiratory failure

- Late-onset Pompe disease
 - *GAA* (AR)

Hereditary

Acquired

Nemaline myopathy

- NEB, etc (12 genes)

• Hereditary myopathy with early resp failure (HMERF)

- TTN (exon 343) (AD)
- Rigid spine muscular dystrophy (RSMD)
 - SELENON (AR)
- Early-onset myopathy, areflexia, respiratory distress, and dysphagia (EMARDD)
 - *MEGF10* (AR)
- Sporadic late-onset nemaline myopathy (SLONM)
- Anti-mitochondrial M2 myositis

Clinical manifestations associated with respiratory failure

- Respiratory
 - Dyspnea, orthopnea
 - Frequent respiratory infections
 - Weak coughing
- Sleep-related
 - Sleep apnea
 - Daytime sleepiness
 - Nightmare

- Others
 - Morning headache
 - Loss of appetite
 - Poor concentration
 - Anxiety and depression

Teaching NeuroImage: Axial muscle atrophy in adult-onset Pompe disease

Neurology. 2008 Mar 4;70(10):e36

LOPD Normal **Diaphragm atrophy**

HMERF TTN

Rigid spine SELENON

Nemaline MP NEB

Control



Axial CT at aortic hiatus level

- useful for evaluating diaphragmatic crus





https://teachmeanatomy.info/thorax/muscles/diaphragm/

Thorac Surg Clin. 2007 Nov;17(4):449-61

Differential diagnosis on muscle pathology

Article abstract—Two unrelated 16-year-old boys had mental retardation, cardiomegaly, and proximal myopathy. One also had hepatomegaly. Histochemistry and electronmicroscopy of muscle biopsies showed lysosomal glycogen storage resembling acid maltase deficiency. Biochemical studies of skeletal muscle showed increased content of glycogen of normal structure; acid α -glucosidase activity in both urine and muscle was normal. Other enzymes of glycogen metabolism were also normal. The cause of this apparently generalized glycogenosis with no demonstrable enzyme defect is unknown.

NEUROLOGY (Ny) 31: 51-57, January 1981

Lysosomal glycogen storage disease with normal acid maltase

Moris J. Danon, M.D., Shin J. Oh, M.D., Salvatore DiMauro, M.D., Jose R. Manaligod, M.D., Ph.D., Abe Eastwood, Ph.D., Sakkubai Naidu, M.D., and Louis H. Schliselfeld, Ph.D.

Danon disease

• X-linked disease

	Male	Female
Onset	10 y ~	30 y ~
Diagnosis	17 ± 7 y	38 ± 12 y
Death	19 ± 6 y	40 ± 7 y

Age range – LOPD

- Clinical features
 - Cardiomyopathy 100%
 - Myopathy
 - Weakness / Fatigability 80%
 - CK elevation 100%
 - Mental retardation 70%
 - Retinopathy

Clinical features – different!

Pompe disease

Danon disease

Autophagic vacuoles with unique sarcolemmal features (AVSF)





Danon disease different from Pompe disease

- Clinical LOPD age but with cardiomyopathy
- Pathological Different autophagic vacuoles

Adult-onset Pompe disease





Acid phosphatase

ACCES? Tsuburaya RS, et al. Neuromuscul Disord. 2012 May;22(5):389-93

1200

5 3 62 M

9

ACP-positive global cytoplasmic inclusions

Occurrence





Patients on ERT

October 2023

	Japan	Taiwan
Infantile	15	66
Late-onset	78	27
Childhood	50	
Adult-onset	28	
	93	93

Neuromuscular

Muscle biochemical and pathological diagnosis in Pompe disease

Yoshihiko Saito 💿 ,¹ Kimitoshi Nakamura,² Tokiko Fukuda,³ Hideo Sugie,⁴ Shinichiro Hayashi,¹ Satoru Noguchi,¹ Ichizo Nishino 💿 ¹





2408 muscle biopsies in 2.5 years July 2015 – January 2018

J Neurol Neurosurg Psychiatry. Online ahead of print

Muscle biopsy diagnosis (Annual) As of December 31, 2022



Neuromuscular

Muscle biochemical and pathological diagnosis in Pompe disease

Yoshihiko Saito ¹ Kimitoshi Nakamura,² Tokiko Fukuda,³ Hideo Sugie,⁴ Shinichiro Hayashi,¹ Satoru Noguchi,¹ Ichizo Nishino ¹

2408 muscle biopsies in 2.5 years July 2015 – January 2018

J Neurol Neurosurg Psychiatry. Online ahead of print









Pathologically diagnosed Pompe disease



Saito Y et al. J Neurol Neurosurg Psychiatry. Online ahead of print



Neurology. 2014 Mar 4;82(9):e73-5

Conclusions

- LOPD Needs to cast a wider net
 - Proximal weakness, respiratory failure, high CK
- Helpful findings on laboratory tests
 - Muscle imaging
 - Glut med/min, paraspinal, subscapularis, diaphragm
 - Muscle pathology
 - ACP-positive global cytoplasmic inclusions
 - EMG
 - Myotonic discharge (paraspinal m.)

→ DBS

H Muscle biopsy

The video shows the recommended surgical technique of muscle biopoy



E Fixation of the biopsied muscle

The video shows the recommended techniques of freeze fluction (for histochemistry and immunohistochemistry) and glutaraidentyde fluction (for electron microscopic study) for biopsied muscle. Biopsied muscles should NOT be fixed with formalin unless there is a specific reason. Correct freeze fluction technique must always be used to avoid artifacts which are most frequently caused by inappropriate maneuver during the fluction procedure or mishandling of the frozen sample.



Teaching Videos for Muscle Biopsy and Fixation

https://www.ncnp.go.jp/nin/guide/r1/video_e.html



Acknowledgments



Hamamatsu Medical University

- Tokiko FUKUDA
- Hide SUGIE



- Kumamoto University
 - Kimitoshi NAKAMURA



Tokyo Women's Medical University

– Keiko ISHIGAKI



Kaohsiung Medical University

- Dr. Wen-Chen LIANG
- Dr. Yuh-Jyh JONG



NCNP Hospital

- Madoka MORI
- Yasushi OYA
- Ayako HATTORI (Currently, Nagoya City Univ)
- Masayuuki SASAKI



Department of Neuromuscular Research, National Institute of Neuroscience, NCNP

– Yoshihiko SAITO